

Author index

- Aalders, J. See Willemse, P.H.B., 236
Aalders, J.G. See Tinga, D.J., 83, 179
Abeler, V.M., Kjørstad, K.E. & Berle, E. Carcinoma of the endometrium in Norway: a histopathological and prognostic survey of a total population, 9
- Baak, J.P.A. See Buist, M.R., 23
Baldetorp, B. See Horvath, G., 101
Barrada, M. See Sevelde, P., 160
Barrett, R.J. See Young, D.S., 175
Bauknecht, T. See Birmelin, G., 66
Baur, M. See Sevelde, P., 160
Beattie, G. See Fiskén, J., 134
Berle, E. See Abeler, V.M., 9
Bichel, P. See Mogensen, O., 141
Billi, G., Venturini, M., Piccini, D., Parodi, S., Rosso, R., Conte, P.F. & Russo, P. Synergistic cytotoxic effects of recombinant human tumor necrosis factor and Etoposide (VP16) or Doxorubicin on A2774 human epithelial ovarian cancer cell line, 147
Birmelin, G., Zimmer, V., Sauerbrei, W., Pfeleiderer, A. & Bauknecht, T. Relationship between epidermal growth factor receptor (EGF-R) and various prognostic factors in human endometrial carcinoma, 66
Blickstein, I. See Piura, B., 189
Bock, J.E. See Hording, U., 314
Boeryd, B. See Högberg, T., 198
Boonstra, H. See Nanninga, A.G., 107
Boonstra, H. See Tinga, D.J., 179
Boonstra, H. See Willemse, P.H.B., 236
Bouma, J. See Tinga, D.J., 83, 179
Bouma, J. See Weijmar Schultz, W.C.M., 281
Brammah-Carr, S. See Van Haaften-Day, C., 41
Brown, E. See Muntz, H.G., 163
Buckley, C.H. See Hale, R.J., 79
Buckley, C.H. See Logue, J.P., 323
Buist, M.R., Kenemans, P., Vermorken, J.B., Golding, R.P., Burger, C.W., Den Hollander, W., Van Kamp, G.J., Van Lingén, A., Teule, G.J.J., Baak, J.P.A. & Roos, J.C. Radioimmunotargeting in ovarian carcinoma patients with indium-111 labeled monoclonal antibody OV-TL3 F(ab')₂: pharmacokinetics, tissue distribution, and tumor imaging, 23
Burger, C.W. See Buist, M.R., 23
Burke, T.W. See Messing, M.J., 295
- Cameron, R. See Horvath, G., 101
Cary, A., Free, K.E., Wright, R.G. & Shield, P.W. Carcinoma of the cervix—recurrences in Queensland 1982–1986, 207
Chao, K.C. See Ng, H.T., 75
Chen, Y.K. See Ng, H.T., 75
Clavero, P.A., Nogales, F.F., Ruiz-Avila, I., Linares, J. & Concha, A. Regression of peritoneal leiomyomatosis after treatment with gonadotropin releasing hormone analogue, 52
- Colucci, G.A. See Resta, L., 307
Concha, A. See Clavero, P.A., 52
Conte, P.F. See Billi, G., 147
Coppleson, M. See Tattersall, M.H.N., 244
Curtin, J.P. See Robinson, W.R., 113
Czernobilsky, B. See Piura, B., 189
- Daugaard, S. See Hording, U., 314
Davies, S. See Van Haaften-Day, C., 41
De Vries, E.G.E. See Nanninga, A.G., 107
De Vries, E.G.E. See Willemse, P.H.B., 236
Dembo, A.J. See Milosevic, M.F., 225
Den Hollander, W. See Buist, M.R., 23
Dgani, R. See Piura, B., 189
Dittrich, C. See Sevelde, P., 160
- Edwards, B.G. See Leary, J.A., 291
El-Khatib, S. See Stanbridge, C.M., 92
- Farnsworth, A. See Wain, G.V., 318
Ferno, M. See Horvath, G., 101
Fiskén, J., Roulston, J.E., Beattie, G., Hayes, D.F. & Leonard, R.C.F. Investigation of the c-neu proto-oncogene related protein, p185, in the serum of primary epithelial ovarian cancer patients, 134
Fitz, R. See Sevelde, P., 160
Fontein, D.L. See Willemse, P.H.B., 236
Free, K.E. See Cary, A., 207
Free, K.E. See McGuckin, M.A., 119
Friedlander, M.L. See Leary, J.A., 291
- Gershenson, D.M. See Messing, M.J., 295
Glezerman, M. See Piura, B., 189
Golding, R.P. See Buist, M.R., 23
Griffiths, M., Sanderson, D. & Penna, L.K. Cervical epithelial abnormalities among women with vulval warts—no more common than among controls, 49
Grimshaw, R.N. See Murdoch, J.B., 129
Gründler, N. See Petru, E., 252
Guerrieri, C. See Högberg, T., 198
- Habeshaw, T. & Pinion, S.B. The incidence of persistent functioning endometrial tissue following successful radiotherapy for cervical carcinoma, 332
Hacker, N.F. See Wain, G.V., 318
Hahn, D.E.E. See Weijmar Schultz, W.C.M., 281
Hale, R.J. See Logue, J.P., 323
Hale, R.J., Ryder, W.D.J., Wilcox, F.L., Buckley, C.H. & Tindall, V.R. Cervical carcinoma: a hazard model in early stage disease, 79
Hayes, D.F. See Fiskén, J., 134
Heintz, A.P.M. See Van Der Velden, J., 157
Helmerhorst, Th.J.M. Clinical significance of endocervical curettage as part of colposcopic evaluation. A review, 256
Hittson, J. See Högberg, T., 198

- Högberg, T., Wang, G., Risberg, B., Guerrieri, C., Hittson, J., Boeryd, B., Kågedal, B. & Simonsen, E. Nuclear morphology: a strong prognostic factor for survival after secondary surgery in advanced ovarian cancer, 198
- Holm, L. See Tholander, B., 271
- Homesley, H. D. See Young, D.S., 175
- Hopkins, M.P. See Singh, T.T., 220
- Hørding, U., Daugaard, S. & Bock, J.E. Human papillomavirus, Epstein-Barr virus, and cervical carcinoma in Greenland, 314
- Horvath, G., Fernö, M., Baldetorp, B., Cameron, R. & Ranstam, J. Characterization of an estradiol-independent but estradiol-responsive growth phenotype in a human endometrial adenocarcinoma heterotransplanted into nude mice, 101
- Hoskins, P.J., McMurtrie, E. & Swenerton, K.D. A phase II trial of intravenous etoposide (VP-16-213) in epithelial ovarian cancer resistant to cisplatin or carboplatin: clinical and serological evidence of activity, 35
- Houghton, C.R.S. See Leary, J.A., 291
- Hunter, R.D. See Logue, J.P., 323
- Iversen, T. See Kaern, J., 169
- Jakobsen, A. See Mogensen, O., 141
- Joy, G.J. See McGuckin, M.A., 119
- Kaern, J., Iversen, T., Tropé, C., Pettersen, E.O. & Nesland, J.M. Flow cytometric DNA measurements in squamous cell carcinoma of the vulva: an important prognostic method, 169
- Kågedal, B. See Högberg, T., 198
- Kan, Y.Y. See Ng, H.T., 75
- Kavanagh, J.J. See Messing, M.J., 295
- Kefford, R.F. See Leary, J.A., 291
- Kenemans, P. See Buist, M.R., 23
- King, L.A., Okagaki, T. & Twiggs, L.B. Resolution of pulmonary metastases with chemotherapy in a patient with placental site trophoblastic tumor, 328
- Kiviranta, A. See Tholander, B., 271
- Kjørstad, K.E. See Abeler, V.M., 9
- Kloppenburg, M. See Willemse, P.H.B., 236
- Kooyman, C.D. See Van Der Velden, J., 157
- Kujawa, M. See Kupryjańczyk, J., 152
- Kupryjańczyk, J. & Kujawa, M. Signet-ring cells in squamous cell carcinoma of the cervix and in non-neoplastic ectocervical epithelium, 152
- Lahousen, M. See Petru, E., 252
- Leary, J.A., Edwards, B.G., Houghton, C.R.S., Kefford, R.F. & Friedlander, M.L. Amplification of HER-2/neu oncogene in human ovarian cancer, 291
- Lentz, S.S. See Young, D.S., 175
- Leonard, R.C.F. See Fiske, J., 134
- Linares, J. See Clavero, P.A., 52
- Lindgren, A. See Tholander, B., 263, 271
- Logue, J.P., Hale, R.J., Wilcox, F.L., Hunter, R.D., Buckley, C.H. & Tindall, V.R. Carcinoma of the cervix: an analysis of prognostic factors, treatment and patterns of failure following Wertheims hysterectomy, 323
- Lowe, D.G. See Van Dam, P.A., 57
- McGuckin, M.A., Ramm, L.E., Joy, G.J., Free, K.E. & Ward, B.G. Preoperative discrimination between ovarian carcinoma, non-ovarian gynecological malignancy and benign adnexal masses using serum levels of CA125 and the polymorphic epithelial mucin antigens CASA, OSA and MSA, 119
- Maclean, G.D. See Palmer, M.C., 301
- Maclean, G.D. See Pearcey, R.G., 215
- McMurtrie, E. See Hoskins, P.J., 35
- Messing, M.J., Gershenson, D.M., Morris, M., Burke, T.W., Kavanagh, J.J. & Wharton, J.T. Primary treatment failure in patients with malignant ovarian germ cell neoplasms, 295
- Mikosch, P. See Petru, E., 252
- Milosevic, M.F., Dembo, A.J. & Thomas, G.M. The clinical significance of malignant peritoneal cytology in stage I endometrial carcinoma, 225
- Mogensen, O., Sørensen, F.B., Bichel, P. & Jakobsen, A. Nuclear volume and prognosis in ovarian cancer, 141
- Monaghan, J.M. See Murdoch, J.B., 129
- Moore, J.S. See Young, D.S., 175
- Morgan, P.R. See Murdoch, J.B., 129
- Morris, M., See Messing, M.J., 295
- Morrow, C.P. See Robinson, W.R., 113
- Mulder, N.H. See Willemse, P.H.B., 236
- Muntz, H.G. & Brown, E. Lactic acidosis and hypoglycemia: a metabolic complication of advanced gynecologic malignancy, 163
- Murdoch, J.B., Grimshaw, R.N., Morgan, P.R. & Monaghan, J.M. The impact of loop diathermy on management of early invasive cervical cancer, 129
- Nanninga, A.G., Willemse, P.H.B., Boonstra, H. & De Vries, E.G.E. Low complication rate during intraperitoneal therapy through a totally implanted peritoneal access port in patients with ovarian cancer, 107
- Nesland, J.M. See Kaern, J., 169
- Ng, H.T., Shyu, S.K., Chen, Y.K., Yuan, C.C., Chao, K.C. & Kan, Y.Y. A scoring system for predicting recurrence of cervical cancer, 75
- Nogales, F.F. See Clavero, P.A., 52
- Okagaki, T. See King, L.A., 328
- Palmer, M.C., Shepert, E., Schepansky, A. & Maclean, G.D. Novel, dose intensive, single-agent cisplatin in the first-line management of advanced stage ovarian cancer, 301
- Parodi, S. See Billi, G., 147
- Pearcey, R.G. & Maclean, G.D. A phase I/II study combining radical radiotherapy with concurrent cisplatin in the treatment of advanced squamous cell carcinoma of the cervix, 215
- Penna, L.K. See Griffiths, M., 49
- Persad, R.V. See Stanbridge, C.M., 92
- Pesce Delfino, V. See Resta, L., 307
- Petru, E., Schmidt, F., Mikosch, P., Pickel, H., Lahousen, M., Tamussino, K., Gründler, N. & Posch, E. Abdominopelvic computed tomography in the preoperative evaluation of suspected ovarian masses, 252

- Pettersen, E.O. See Kaern, J., 169
 Pfeleiderer, A. See Birmelin, G., 66
 Piccini, D. See Billi, G., 147
 Pickel, H. See Petru, E., 252
 Pinion, S.B. See Habeshaw, T., 332
 Piura, B., Dgani, R., Blickstein, I., Yanai-Inbar, I., Czernobilsky, B. & Glezerman, M. Epithelial ovarian tumors of borderline malignancy: a study of 50 cases, 189
 Posch, E. See Petru, E., 252
 Price, J. See Singh, T.T., 220
- Ramirez, C. See Tattersall, M.H.N., 244
 Ramm, L.E. See McGuckin, M.A., 119
 Ranstam, J. See Horvath, G., 101
 Resta, L., Ricco, R., Colucci, G.A., Troia, M., Russo, S., Vacca, E. & Pesce Delfino, V. A new approach to the histologic study of ovarian tumors by analytical morphometry, 307
 Ricco, R. See Resta, L., 307
 Risberg, B. See Högberg, T., 198
 Robinson, W.R., Curtin, J.P. & Morrow, C.P. Operative staging and conservative surgery in the management of low malignant potential ovarian tumors, 113
 Roos, J.C. See Buist, M.R., 23
 Rosso, R. See Billi, G., 147
 Roulston, J.E. See Fiske, J., 134
 Ruiz-Avila, I. See Clavero, P.A., 52
 Russell, P. See Van Haften-Day, C., 41
 Russo, P. See Billi, G., 147
 Russo, S. See Resta, L., 307
 Ryder, W.D.J. See Hale, R.J., 79
- Salzer, H. See Sevelde, P., 160
 Sanderson, D. See Griffiths, M., 49
 Sauerbrei, W. See Birmelin, G., 66
 Schepansky, A. See Palmer, M.C., 301
 Schmidt, F. See Petru, E., 252
 Schuen, R. See Singh, T.T., 220
 Sevelde, P., Vavra, N., Fitz, R., Barrada, M., Salzer, H., Baur, M. & Dittrich, C. Goserelin a GnRH-analogue as third-line therapy of refractory epithelial ovarian cancer, 160
 Shepert, E. See Palmer, M.C., 301
 Shepherd, J.H. See Van Dam, P.A., 57
 Shield, P.W. See Cary, A., 207
 Shyu, S.K. See Ng, H.T., 75
 Simonsen, E. See Högberg, T., 198
 Singh, T.T., Hopkins, M.P., Price, J., Schuen, R. Myxoid liposarcoma of the broad ligament, 220
 Sleijfer, D. Th. See Willemse, P.H.B., 236
 Sørensen, F.B. See Mogensen, O. 141
 Stanbridge, C.M., Suleman, B.A., Persad, R.V. & El-Khatib, S. A cervical smear review in women developing cervical carcinoma with particular reference to age, false negative cytology and the histologic type of the carcinoma, 92
 Sténson, S. See Tholander, B., 263
 Strang, P. See Tholander, B., 271
 Suleman, B.A. See Stanbridge, C.M., 92
 Swenerton, K.D. See Hoskins, P.J., 35
- Tamussino, K. See Petru, E., 252
- Tattersall, M.H.N., Ramirez, C. & Coppleson, M. A randomized trial comparing platinum-based chemotherapy followed by radiotherapy vs. radiotherapy alone in patients with locally advanced cervical cancer, 244
 Taube, A. See Tholander, B., 263, 271
 Teule, G.J.J. See Buist, M.R., 23
 Tholander, B., Lindgren, A., Taube, A. & Sténson, S. Immunohistochemical detection of CA-125 and carcinoembryonic antigen in ovarian tumours in relation to corresponding preoperative serum levels, 263
 Tholander, B., Strang, P., Lindgren, A., Holm, L., Kiviranta, A. & Taube, A. Tissue expression of CA-125 and carcinoembryonic antigen in ovarian carcinoma in relation to nuclear DNA content, histologic grade, and patient survival, 271
 Thomas, G.M. See Milosevic, M.F., 225
 Tidy, J.A. & Wrede, D. Tumor suppressor genes: new pathways in gynecological cancer, 1
 Tindall, V.R. See Hale, R.J., 79
 Tindall, V.R. See Logue, J.P., 323
 Tinga, D.J., Bouma, J. & Aalders, J.G. Patients with squamous cell versus adeno(squamous) carcinoma of the cervix, what factors determine the prognosis? 83
 Tinga, D.J., Boonstra, H. & Aalders, J.G. Symptomatology, localization and treatment of recurrent cervical carcinoma, 179
 Troia, M. See Resta, L., 307
 Tropé, C. See Kaern, J., 169
 Twiggs, L.B. See King, L.A., 328
- Vacca, E. See Resta, L. 307
 Van Dam, P.A., Watson, J.V., Lowe, D.G. & Shepherd, J.H. Flow cytometric DNA analysis in gynecological oncology, 57
 Van De Wiel, H.B.M. See Weijmar Schultz, W.C.M., 281
 Van Der Velden, J., Kooyman, C.D., Van Lindert, A.C.M. & Heintz, A.P.M. A stage Ia vulvar carcinoma with an inguinal lymph node recurrence after local excision. A case report and literature review, 157
 Van Haften-Day, C., Russell, P., Davies, S. & Brammah-Carr, S. An *in vitro* study of ovarian atypical proliferating (borderline) serous tumors, 41
 Van Kamp, G.J. See Buist, M.R., 23
 Van Lindert, A.C.M. See Van Der Velden, J., 157
 Van Lingen, A. See Buist, M.R. 23
 Vavra, N. See Sevelde, P., 160
 Venturini, M. See Billi, G., 147
 Vermoken, J.B. See Buist, M.R., 23
- Wain, G.V., Farnsworth, A. & Hacker, N.F. Cervical carcinoma after negative Pap smears: evidence against rapid-onset cancers, 318
 Wang, G. See Högberg, T., 198
 Ward, B.G. See McGuckin, M.A., 119
 Watson, J.V. See Van Dam, P.A., 57
 Weijmar Schultz, W.C.M., Van De Wiel, H.B.M., Hahn, D.E.E. & Bouma, J. Psychosexual functioning after treatment for gynecological cancer: an integrative model, review of determinant factors and clinical guidelines, 281
 Wharton, J.T. See Messing, M.J., 295

- Wilcox, F.L. See Hale, R.J., 79
Wilcox, F.L. See Logue, J.P., 323
Willemse, P.H.B. See Nanninga, A.G., 107
Willemse, P.H.B., De Vries, E.G.E., Kloppenburg, M.,
Fontein, D.L., Aalders, J.G., Boonstra, H., Mulder, N.H. &
Sleijfer, D. Th. Carboplatin with cyclophosphamide in
patients with advanced ovarian cancer: an efficacy and
quality-adjusted survival analysis, 236
Wrede, D. See Tidy, J.A., 1
Wright, R.G. See Cary, A., 207
Yanai-Inbar, I. See Piura, B., 189
Young, D.S., Lentz, S.S., Barrett, R.J., Homesley, H.D. &
Moore, J.S. Outpatient management of malignant ascites
using ultrasound, a trocar, and a Tenckhoff catheter, 175
Yuan, C.C. See Ng, H.T., 75
Zimmer, V. See Birmelin, G., 66

Keyword index

- adenocarcinoma, 83
adenosquamous carcinoma, 83
adjuvant chemotherapy, 189
advanced disease, 160
amplification, 291
analytical morphometry, 307
ascites, 175
- benign gynecological disease, 119
beta hCG, 328
borderline, 113
borderline malignancy, 189
borderline ovarian tumors, 41
- CA125, 119
CA-125, 263, 271
cancer, 295
carboplatin, 236
carcinogenesis, 314
carcinoma, 92, 323
carcinoma of the cervix, 129
CEA, 263, 271
cervical cancer, 75, 207, 318
cervical carcinoma, 79, 83
cervical intraepithelial neoplasia, 256
cervical screening, 49
cervix, 57, 92, 323
cervix cancer, 215
cervix uteri, 152
cervix-neoplasia, 332
chemotherapy, 147, 236, 244, 295
CIN, 49
cisplatin, 107, 236
colposcopy, 49, 256
complications, 113
computed tomography, 252
concurrent radiotherapy cisplatin, 215
conservative surgery, 189
coping, 281
cure rate of recurrent cervical carcinoma, 179
cytology, 92, 207, 318
cytotoxicity, 147
- diagnostic methods, 23
disseminata, 52
DNA analysis, 57
DNA ploidy, 169
dose intensity, 301
Doxorubicin, 147
- EBV-DNA, 314
EGF receptor, 66
EGF-like factor, 66
ELISA, 134
endometrial adenocarcinoma, 101
- endometrial carcinoma, 9, 66, 225
endometrium, 57, 332
endocervical curettage, 256
epithelial ovarian tumors, 189
estradiol-independent growth, 101
etoposide, 35, 107
exenteration, 179
- female, 295
flow cytometry, 57, 169, 271
- germ cell, 295
GnRH-analogue, 160
Goserelin, 160
Greenland, 314
gynecological cancer, 281
gynecologic oncology, 175
- HER-2/neu, 291
heuristic model, 79
histology, 207, 252
histopathology, 9
hormone replacement therapy, 332
HPV, 1
HPV-DNA, 314
hypoglycemia, 163
- i.p. catheter, 107
immunocytochemistry, 263, 271
immunohistochemistry, 41, 66
interferon-alpha, 107
intraperitoneal, 107
- lactic acidosis, 163
large loop excision, 129
leiomyomatosis, 52
leuprolide acetate, 52
liposarcoma, 220
localization of recurrent cervical carcinoma, 179
locally advanced cervical cancer, 244
low malignancy potential, 189
lymph node metastases, 83
- microinvasive vulvar carcinoma, 157
monitoring, 134
morphometry, 141
mortality, 207
multi-agent chemotherapy, 328
- neoplasms, 163
neoplasms (embryonal and mixed), 163
neu, 134
nuclear morphometry, 198
oncogene, 291
- oncoprotein, 134
ovarian cancer, 35, 107, 119, 134, 147, 236, 291, 301
ovarian carcinoma, 23, 141, 160, 198
ovarian neoplasms, 263, 271
ovarian serous tumors, 307
ovarian tumours, 252
ovary, 57, 295
- p53, 1
Pap smears, 318
peritoneal cytology, 225
peritoneum, 52
phase II, 35
placental site trophoblastic tumor (PSTT), 328
platinum resistance, 35
polymerase chain reaction/PCR, 314
polymorphic epithelial mucin, 119
primary culture, 41
prognosis, 9, 66, 134, 198, 271, 291
prognostic factors, 79, 83, 169
prognostic parameter, 141
- quality of life, 236
- radioimmunotargeting, 23
radiotherapy, 323, 332
rapid-onset cancers, 318
Rb, 1
recurrence, 207
recurrent cervical carcinoma, 179
retro-peritoneal lymph nodes, 252
retro-peritoneal sarcoma, 220
rHuTNF, 147
- sarcoma, 220
scoring system, 75
secondary surgery, 198
serodiagnosis, 263
sexual assessment, 281
sexual functioning, 281
signet-ring cell, 152
single-agent cisplatin, 301
smooth muscle tumor, 52
squamous carcinoma, 152
squamous cell carcinoma, 169
squamous cell carcinoma of the cervix, 314
stage, 207
stage I, 129
staging, 113
stereology, 141
surgery, 113, 295
symptoms of recurrent cervical carcinoma, 179

Tenckhoff, 175

TGF α , 66

treatment of recurrence, 179

trophoblastic disease, 328

tumor associated antigen, 119

tumor diameter, 83

tumor hypoglycemia, 163

tumor suppressor genes, 1

tumor antigens, 263, 271

ultrasound, 175

uterine neoplasm, 9

uterine neoplasms, 163

VP16, 147

vulva, 169

vulval warts, 49

vulvar carcinoma, 157

Wertheims, 323

